key: cord-0805666-t73oioqv
authors: Hu, Ling; Chen, Shaoqiu; Fu, Yuanyuan; Gao, Zitong; Long, Hui; Wang, Jian-ming; Ren, Hong-wei; Zuo, Yi; Li, Huan; Wang, Jie; Xu, Qing-bang; Yu, Wen-xiong; Liu, Jia; Shao, Chen; Hao, Jun-jie; Wang, Chuan-zhen; Ma, Yao; Wang, Zhanwei; Yanagihara, Richard; Deng, Youping
title: Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Hospitalized Patients in Wuhan, China
date: 2020-05-03
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa539
sha: 2f950d135df139cc5c6a50233f260e4518e2c484
doc_id: 805666
cord_uid: t73oioqv

BACKGROUND: With evidence of sustained transmission in more than 190 countries, coronavirus disease 2019 (COVID-19) has been declared a global pandemic. Data are urgently needed about risk factors associated with clinical outcomes. METHODS: A retrospective review of 323 hospitalized patients with COVID-19 in Wuhan was conducted. Patients were classified into three disease severity groups (non-severe, severe, and critical), based on initial clinical presentation. Clinical outcomes were designated as favorable and unfavorable, based on disease progression and response to treatments. Logistic regression models were performed to identify risk factors associated with clinical outcomes, and log-rank test was conducted for the association with clinical progression. RESULTS: Current standard treatments did not show significant improvement in patient outcomes. By univariate logistic regression analysis, 27 risk factors were significantly associated with clinical outcomes. Multivariate regression indicated age over 65 years (p<0.001), smoking (p=0.001), critical disease status (p=0.002), diabetes (p=0.025), high hypersensitive troponin I (>0.04 pg/mL, p=0.02), leukocytosis (>10 x 10(9)/L, p<0.001) and neutrophilia (>75 x 10(9)/L, p<0.001) predicted unfavorable clinical outcomes. By contrast, the administration of hypnotics was significantly associated with favorable outcomes (p<0.001), which was confirmed by survival analysis. CONCLUSIONS: Hypnotics may be an effective ancillary treatment for COVID-19. We also found novel risk factors, such as higher hypersensitive troponin I, predicted poor clinical outcomes. Overall, our study provides useful data to guide early clinical decision making to reduce mortality and improve clinical outcomes of COVID-19.

Coronavirus disease 2019 (COVID-19) is a potentially lethal respiratory illness caused by a newly identified coronavirus, named SARS coronavirus 2 (SARS-CoV-2), which was first recognized in December 2019 in Wuhan, in Hubei Province, China. 1,2 COVID-19 has spread rapidly to more than 190 countries, and as of April 7, 2020, 1,431,689 confirmed cases and 82,074 deaths have been officially reported worldwide. [3] [4] [5] [6] [7] With sustained transmission on six continents, the World Health Organization (WHO) has recently declared COVID-19 as a global pandemic.

Most previous studies of COVID-19 have focused primarily on epidemiological and clinical characteristics. [8] [9] [10] [11] [12] [13] Wang and co-workers compared the clinical features of 138 hospitalized patients with non-severe and severe COVID-19. 10 Guan and colleagues updated the clinical characteristic and disease severity in 1,099 laboratory-confirmed cases throughout China. 12 Only a few studies have investigated risk factors associated with clinical outcomes. 14, 15 So, it is urgent to identify potential novel risk factors and treatments associated with patient-centered outcomes of COVID-19.

In this study, we analyzed the initial clinical presentation and baseline laboratory test results, as well as clinical course, of 323 hospitalized patients with COVID-19, in Wuhan, to identify risk factors associated with clinical outcomes for improving management guidelines.

A c c e p t e d M a n u s c r i p t

The institutional ethics board of Tianyou Hospital, an affiliate of the Wuhan University of Science and Technology, approved the conduct of this retrospective review. Oral consent was obtained from patients and written informed consent was waived. Tianyou Hospital is one of several designated hospitals for the treatment of COVID-19 in Wuhan.

Of 330 patients with COVID-19 hospitalized from January 8 to February 20, 2020, seven patients were excluded due to incomplete medical records because they elected to be transferred to other hospitals, leaving 323 patients in the study. The final follow-up date was March 10, 2020.

Clinical signs, disease onset, laboratory tests (including RT-PCR and chest computer tomography, or CT), treatments, co-morbidities, complications, and outcomes data were collected from electronic medical records (EMR). All raw data were initially evaluated by trained physicians. More details about laboratory procedures are provided in the appendix. Based on the clinical presentation at the time of admission, patients were categorized into one of three groups: non-severe, severe and critical. And their initial clinical presentation and test results at baseline were associated with either favorable or unfavorable clinical outcomes. More details about clinical classification are provided in the appendix.

Disease improvement or favorable clinical outcome included full recovery and discharge, progression from critical/severe to non-severe disease status, PCR positive to negative and/or maintenance of non-severe status. Disease progression or unfavorable clinical outcome included death, progression from non-severe to severe/critical disease status or severe to critical status, and/or maintenance of severe or critical status.

A c c e p t e d M a n u s c r i p t

Chi-square test or Fisher exact test was used for categorical variables measurements. For continuous variables, student T-test or Mann-Whitney test was used. Multiple imputation was conducted to handle missing data. 18 Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using univariate and multivariate logistic regression models. For survival analysis, the survival time was defined as the interval from the date of admission to the date of death or discharge. The association of risk factors with clinical outcome was analyzed using the Kaplan-Meier method and log-rank test. All analyses were implemented with R software (version 3.6.2) or Statistical Analysis System (SAS) software (version 9.4, SAS Institute Inc., Cary, NC). All P values were two-sided, and those < 0.05 were considered as statistically significant.

Of the 323 COVID-19 patients, 186 (57.6%) were RT-PCR positive and 137 (42.4%) patients were RT-PCR negative but had typical chest CT image, respiratory symptoms and compatible blood test results at the time of admission. At the end of the study, 252 patients had recovered and were discharged, 35 patients had died (overall case fatality rate, 10.8%), and 36 patients were still hospitalized.

Based on their initial clinical presentation, the 323 patients were classified into the nonsevere (151), severe (146) and critical (26) A c c e p t e d M a n u s c r i p t On admission, fever (83.9%, 271/323) and cough (50.8%, 164/323) were the most common symptoms, while dyspnea (4.3%, 14/323), chest distress (0.9%, 3/323) and headache (0.9%, 3/323) were uncommon.

Test results at baseline rather than the highest value during hospitalization were used to predict clinical outcome. Patients were enrolled from January 8 to February 20, 2020, and the final follow-up date was March 10, 2020. The median hospital length of stay was 18 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) days. Favorable outcomes were recorded in 260 patients and unfavorable outcomes in 63 patients. Among the three disease severity groups, 86.8% (131/151) and 84.9% (124/146) of patients in the non-severe and severe groups, respectively, had favorable outcomes. By contrast, 80.8% (21/26) of patients in the critical group had unfavorable outcomes (Fig. 1A) . Patients older than 65 years showed more unfavorable than favorable outcomes. Patients with diabetes and body mass index (BMI) of 30

were more likely to have unfavorable outcomes (Table 1) .

Dexzopiclone, a cyclopyrrolone-class drug for insomnia, was administered at a dose of 1.0 mg per day to 82 patients (25.4%) for the duration of their hospitalization. Overall, favorable outcomes were recorded in 77 of these patients and all were discharged (Table 1) . Of the five patients receiving hypnotics who had unfavorable outcomes, only 1 died. In comparing hypnotics and non-hypnotics use in patients within the three disease groups, favorable clinical outcomes were more prevalent among patients on hypnotics (94.7% vs. 88.5% for non-severe, 95% vs. 74.6% for severe, and 66.7% vs. 13.0% for critical) (p<0.05) (Fig. 1B) . And favorable clinical outcomes were associated with the administration of hypnotics among RT-PCR-positive and RT-PCR-negative patients in each disease severity group ( Fig. 1C and 1D ).

A c c e p t e d M a n u s c r i p t

The radiologic and laboratory test results are summarized in Table 2 (a complete version is available   as Supplementary Table S1 ). CT abnormalities were found in 314 patients. Ground-glass opacity (GGO) findings were bilateral in 55.0% (83/151), 52.1% (76/146) and 26.9% (7/26) of patients in the non-severe, severe and critical disease groups, respectively. Multiple bilateral pulmonary consolidations and intralocular interstitial thickening were observed more frequently among patients with unfavorable outcomes (11.1%, 7/63) than those with favorable outcomes (0.8%, 2/260). Representative CT images related to clinical outcomes are shown in Fig. S1 .

Laboratory findings between patients with favorable and unfavorable outcomes showed differences in leukocyte and neutrophil counts and C-reactive protein, as well as lactate dehydrogenase, creatinine, alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, glucose, and serum amyloid A, which were all higher among patients with unfavorable outcomes. Lymphopenia also occurred among 83.6% of patients with unfavorable outcomes, while D-dimer showed no significant differences.

RT-PCR was positive more often among patients in the critical (84.6%) and severe (65.1%) disease groups, than in the non-severe group (45.7%). Patients whose RT-PCR were initially negative also had better clinical outcomes, with only 9.5% (13/137) having unfavorable outcomes.

Results related to treatment and complications are shown in Table 3 . Oseltamivir (69.7%, 225/323), ganciclovir (71.2%, 230/323), and arbidol (208/323, 64.4%) were the three most frequently used antiviral medications. And one or more courses of moxifloxacin, a broadspectrum antibiotic, was administered to 94.1% (304/323) of patients. Also, 60.7% (196/323) of patients were given corticosteroid and glucocorticoid, and 95.7% (309/323) received A c c e p t e d M a n u s c r i p t alternative therapy or traditional Chinese medicine. Kaletra® (lopinavir/ritonavir), an antiretroviral drug for human immunodeficiency virus infection, was more frequently administered to patients in the critical-disease group (46.2%) and in those with unfavorable than favorable outcomes (23.8% vs 5.0%). Interferon-α was also given more often to patients with unfavorable than favorable outcomes (9.5% vs. 6.2%). Other medications showed no significant differences in clinical outcomes.

Oxygen therapy via invasive ventilation and non-invasive ventilation was also given more often to patients with unfavorable clinical outcomes. In comparing the outcome of each treatment within the non-severe or severe or critical disease groups, there was no clear improvement ( Fig. S2 ).

Of the 63 patients with unfavorable outcomes, complications, such as arrhythmia (74.6% vs. 19.6%), acute lung injury (69.8% vs. 21.5%), shock (55.6% vs. 3.1%), acute cardiac injury (33.3% vs. 1.2%), and acute respiratory distress syndrome (20.6% vs. 0%), were significantly more common than in patients with favorable outcomes (Table 3) .

A total of 27 categorical variables were identified in univariate logistic regression analysis, namely: age, smoking, BMI, hypnotics, dyspnea, diabetes, malignancy, cardiovascular and cerebrovascular diseases, serum amyloid A, procalcitonin, hypersensitive troponin I, creatine kinase CMB, lactate dehydrogenase, alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, creatinine, glucose, leukocyte count, neutrophil count, platelet count, RT-PCR at diagnosis, clinical status at admission, bilateral GGO, crazy paving sign, diffuse patchy ground glass and air bronchogram, and multiple bilateral pulmonary consolidation and intralobular interstitial thickening ( (Fig. 2A) .

Patients in the non-severe group showed significantly better survival compared with those in the severe and critical groups (Fig. 2B ). Patients given hypnotics showed significant favorable survival compared with the non-hypnotics (Fig. 2C) , and patients with positive RT-PCR results showed significantly poorer survival compared with those with negative RT-PCR (Fig. 2D ).

In contrast to a previous study, 12 most patients with COVID-19 in the severe group of our series showed favorable clinical outcomes, at approximately the same frequency as in nonsevere cases (84.9% vs 86.8%), and survival analysis demonstrated consistently higher survival rates in non-severe and severe cases than in critical cases. Although previous studies failed to show that smoking was a risk factor for COVID-19, 9, 15 multivariate analysis in our study demonstrated that smoking was an independent risk factor for unfavorable outcome.

Otherwise, we confirmed findings from other studies 10,12,14 that age over 65 years and leukocytosis with left shift were associated with poorer clinical outcome.

To our knowledge, this is the first report that dexzopiclone, a commonly prescribed hypnotics drug for insomnia, was significantly associated with improved clinical outcome. Patients of the same disease-severity category, who were administered hypnotics, showed better outcome than those not taking hypnotics. For patients in the more severe disease groups, the improvement effect A c c e p t e d M a n u s c r i p t was even more pronounced. Also, in analyzing the effect of hypnotics on RT-PCR-positive and RT-PCR-negative patients separately, we found that hypnotics had a more striking effect on the former.

Moreover, patients administered hypnotics had a better survival rate.

To further rule out bias, we conducted multivariate analysis ( Fig. 2A) to justify other factors.

We found that hypnotics were a significant independent factor (p<0.001), and patients using it had better outcomes.

Patients with COVID-19 are typically very anxious and exhibit sleep deficiency and oxygen insufficiency during disease progression, which may lead to the metabolic dysregulation 19 ,20 and immune system abnormalities 21 . Better sleep quality and stress reduction could be one justification for prescribing hypnotics to COVID-19 patients. That is, hypnotics could help a patient to overcome difficult and prolonged hospitalization (about 2 to 3 weeks), resulting in improved survival and recovery. Dimitrov and colleagues indicated that sleep can exert some immune-supportive effects and potentially enhance effective T-cell responses. 22 In addition, the superior efficacy of dexzopiclone may be due to enhanced gamma aminobutyric acid (GABA) signaling. That is, dexzopiclone can interact with GABAA, and GABAA receptor can magnify responses to GABA. 23 GABA signaling promotes autophagy activation, which improves phagosome maturation and promotes host protection against infections. 24 The beneficial effect of hypnotics on COVID-19 clinical outcomes warrants further investigation in the management of COVID-19 patients.

Until now, several descriptive studies have mentioned the ineffectiveness of current medications irrespective of the disease-severity category 10, 12, 25 . Our data are in general accord. By specifically comparing the effect of standard treatments for patients in the same disease-severity category (Fig. S2) , we were unable to show that any standard therapy could improve clinical outcome. However, since only about 25% of patients in our study were A c c e p t e d M a n u s c r i p t administered hypnotics, we assume that self-healing could be the major reason for the high recovery rate of patients in the non-severe and severe disease groups. That is, COVID-19 is most likely a self-limited disease in the majority of patients. Moreover, the high false-negativity of RT-PCR (about 20-40%) 26 presents a significant burden on health care providers to use their clinical judgment. And chest CT has a higher sensitivity for diagnosis of COVID-19 than RT-PCR. 26 Several underlying reasons, including uneven sensitivities of different detection kits, improper collection of throat swab specimens, and low concentration of virus in samples 27 can lead to the possible deviation in test results. Therefore, including the RT-PCR-negative patients was an important measure to control and prevent the spread of COVID-19 in Wuhan.

We found that patients in the severe or critical disease groups were more likely to be RT-PCR positive. Survival analysis also corroborated that RT-PCR-positive patients showed poorer clinical outcomes.

Since all patients in our study were tested by the same experienced team using the same RT-PCR protocol, we believe the major reason for the negative RT-PCR results in our patient series was due to the low concentration of virus in the throat, which may indicate that patients with negative RT-PCR test might be less likely to infect other people. We found that only a small portion of patients (less than 10%) with negative RT-PCR had unfavorable A c c e p t e d M a n u s c r i p t outcomes. In performing follow-up RT-PCR on patients in the severe disease group with abnormal CT, we found 23 cases whose first test was negative and later tests were positive.

We believe the inclusion of RT-PCR-negative patients with clinically compatible presentation of COVID-19 will help guide clinicians in the care of such patients.

Obesity (BMI 30), hyperglycemia and diabetes, and cardiovascular disease were distinct risk factors for unfavorable clinical outcomes. Other studies also reported that obesity is associated with worse outcome of COVID-19 patients. 28, 29 Angiotensin-converting enzyme-2 (ACE2), which serves as a cell-entry receptor for SARS CoV-2, 30 plays a protective role for both diabetes and cardiovascular diseases. 31, 32 Kuba and colleagues demonstrated that SARS-CoV downregulates ACE2 protein, 33 which could explain why COVID-19 patients with diabetes and cardiovascular disease have worse clinical outcomes.

We found that abnormally high hypersensitive troponin I was an independent predictor for poor clinical outcome. Increased troponin can enhance coagulation activation. 34 In patients with COVID-19, immune damage to the hematopoietic system, ischemic hypoxia-reperfusion injury, and drugs can cause coagulation disorders. 8, [34] [35] [36] [37] We speculate that increased troponin will induce dysfunction of coagulation and thrombus formation with possible pulmonary embolism, which would further aggravate the patient's condition. D-dimer was found to be very significantly different according to the disease-severity status, and a higher proportion of patients with severe (50.7%) and critical (57.1%) disease had D-dimer levels >0.5 mg/L, which is consistent with other studies 10,12 . However, in terms of clinical outcomes, even though the patients with unfavorable outcomes had higher percentage (51.9%) of D-dimer >0.5 mg/L than the patients (40.4%) with favorable outcomes, the difference was not statistically significant.

There were some limitations in our study. Incomplete laboratory test results in some patient records may have caused deviations in statistical analysis. Except for hypnotics, we found that all treatments were ineffective and many treatments showed unwanted side effects, A c c e p t e d M a n u s c r i p t including liver injury. [38] [39] [40] Although we did not conduct separate analysis for RT-PCRpositive and RT-PCR-negative patients, our multivariate analysis identified eight independent risk factors, which were independent of the RT-PCR result.

Although the vast majority of patients recovered, approximately 20% of our hospitalized patient cohort had unfavorable clinical outcomes. To what extent chronic respiratory insufficiency or other organ system sequelae occur in COVID-19 patients will require careful and prolonged followup studies. So far, it seems there is no effective standard treatment. However, we have found that using hypnotics were significantly associated with improved clinical outcome of COVID-19. We also found that some novel risk factors that could predict patient outcome, which can help in early decision making for improving clinical outcomes of COVID-19 patients. for their efforts in collecting the information used in this study. With the permission of the corresponding authors, we can provide participant data without names and identifiers, but not the study protocol, statistical analysis plan, or informed consent form (dengy@hawaii.edu). Data can be provided after the Article is published. Once the data can be made public, the research team will provide an email address for communication. The corresponding author has the right to decide A c c e p t e d M a n u s c r i p t whether to share the data or not based on the research objectives and plan provided. This study was approved by the Ethics Committee of Tianyou Hospital, Affiliated to Wuhan University of Science and Technology (NO202000221).

Oral consent was obtained from patients and written informed consent was waived.

Funded by the Natural Science Foundation of Hubei Province ZRMS2019000029, Top Youth Talent Program in Hubei Province.

We declare no competing interests.

A c c e p t e d M a n u s c r i p t M a n u s c r i p t M a n u s c r i p t M a n u s c r i p t 

A Novel Coronavirus from Patients with Pneumonia in China

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Johns Hopkins Coronavirus Resource Center

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam

Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany

SARS-CoV-2 Infection among Travelers Returning from Wuhan, China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical Characteristics of 138 Hospitalized Patients With

Novel Coronavirus-Infected Pneumonia in Wuhan, China

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a

Cases From the Chinese Center for Disease Control and Prevention

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 2020. 16. Clinical management of severe acute respiratory infection when Novel coronavirus (2019-nCoV) infection is suspected: Interim Guidance

Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls

Sleep and metabolism: an overview

Hypoxia-driven glycolytic and fructolytic metabolic programs: Pivotal to hypertrophic heart disease

The sleep-immunity relationship

Galphas-coupled receptor signaling and sleep regulate integrin activation of human antigen-specific T cells

The mechanism of action of zopiclone

GABAergic signaling linked to autophagy enhances host protection against intracellular bacterial infections

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases

The way to reduce the"false negative results"of 2019 novel coronavirus nucleic acid detection

Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen

Clinical Characteristics of Covid-19 in New York City

Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations

ACE2 and diabetes: ACE of ACEs?

Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications

A crucial role of angiotensin converting enzyme 2

SARS coronavirus-induced lung injury

Enhanced coagulation activation in troponin T-positive unstable angina pectoris

Tissue factor as a link between inflammation and coagulation

Hematological adverse effects and pharmacokinetics of ribavirin in pigs following intramuscular administration

Anticoagulation and coagulation management for ECMO

Liver injury in COVID-19: management and challenges. The Lancet Gastroenterology & Hepatology

Case report on alimentary tract hemorrhage and liver injury after therapy with oseltamivir: A case report

Transcriptional profiling suggests that

*The clinical outcome was categorized into unfavorable and favorable. Unfavorable: patients died, or the condition was getting worse. Favorable: patients discharged, or condition improved

Acute respiratory distress syndrome

A c c e p t e d M a n u s c r i p t M a n u s c r i p t A c c e p t e d M a n u s c r i p t Figure 2